• Mutation; HGNC; HGNC:4778; H3-4; Simple; p.Arg3Ter (c.7C>T); Zygosity=Heterozygous (PubMed=30737244).
  
• Mutation; HGNC; HGNC:6913; MAX; Simple; c.295+1G>A; ClinVar=VCV000186993; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=30737244).
  
• Mutation; HGNC; HGNC:30064; PBRM1; Simple; p.Arg534Ter (c.1600C>T); Zygosity=Homozygous (PubMed=30737244).
  
• Mutation; HGNC; HGNC:9967; RET; Simple; p.Met918Thr (c.2753T>C); ClinVar=VCV000013919; Zygosity=Heterozygous (PubMed=19897677; PubMed=30737244).
  

CLPUB00385
Knuth A., Gabbert H.E., Moll R., Dippold W.G., Meyer zum Buschenfelde K.-H.
Markers in medullary thyroid cancer established in tissue culture.
Proc. Am. Assoc. Cancer Res. 28:83.330-83.330(1987)

PubMed=7736432; DOI=10.1016/0165-4608(94)00185-E
Cooley L.D., Elder F.F.B., Knuth A., Gagel R.F.
Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines.
Cancer Genet. Cytogenet. 80:138-149(1995)

PubMed=19897677; DOI=10.1210/jc.2009-1485; PMCID=PMC2805480
Zhu W., Hai T., Ye L., Cote G.J.
Medullary thyroid carcinoma cell lines contain a self-renewing CD133+ population that is dependent on Ret proto-oncogene activity.
J. Clin. Endocrinol. Metab. 95:439-444(2010)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)